Serum 1,3-beta-D-glucan as a noninvasive test to predict histologic activity in patients with inflammatory bowel disease.


Journal

World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448

Informations de publication

Date de publication:
07 Mar 2021
Historique:
received: 11 11 2020
revised: 11 01 2021
accepted: 18 02 2021
entrez: 17 3 2021
pubmed: 18 3 2021
medline: 15 5 2021
Statut: ppublish

Résumé

1,3-beta-D-glucan (BG) is a ubiquitous cell wall component of gut micro-organisms. We hypothesized that the serum levels of BG could reflect active intestinal inflammation in patients with inflammatory bowel disease. To determine whether the serum BG concentrations correlate with intestinal inflammation. A prospective observational study was performed in a tertiary referral center, from 2016 to 2019, in which serum BG was determined in 115 patients with Crohn's disease (CD), 51 with ulcerative colitis (UC), and 82 controls using a photometric detection kit. Inflammatory activity was determined by ileocolonoscopy, histopathology, magnetic resonance enterography, and biomarkers, including fecal calprotectin (FC), C-reactive protein, and a panel of cytokines. The ability of BG to detect active The serum BG levels were higher in CD patients than in controls ( Serum BG may represent an important novel noninvasive approach for detecting mucosal inflammation and therapeutically monitoring inflammatory bowel diseases, particularly in CD.

Sections du résumé

BACKGROUND BACKGROUND
1,3-beta-D-glucan (BG) is a ubiquitous cell wall component of gut micro-organisms. We hypothesized that the serum levels of BG could reflect active intestinal inflammation in patients with inflammatory bowel disease.
AIM OBJECTIVE
To determine whether the serum BG concentrations correlate with intestinal inflammation.
METHODS METHODS
A prospective observational study was performed in a tertiary referral center, from 2016 to 2019, in which serum BG was determined in 115 patients with Crohn's disease (CD), 51 with ulcerative colitis (UC), and 82 controls using a photometric detection kit. Inflammatory activity was determined by ileocolonoscopy, histopathology, magnetic resonance enterography, and biomarkers, including fecal calprotectin (FC), C-reactive protein, and a panel of cytokines. The ability of BG to detect active
RESULTS RESULTS
The serum BG levels were higher in CD patients than in controls (
CONCLUSION CONCLUSIONS
Serum BG may represent an important novel noninvasive approach for detecting mucosal inflammation and therapeutically monitoring inflammatory bowel diseases, particularly in CD.

Identifiants

pubmed: 33727775
doi: 10.3748/wjg.v27.i9.866
pmc: PMC7941859
doi:

Substances chimiques

Biomarkers 0
Leukocyte L1 Antigen Complex 0
beta-Glucans 0

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

866-885

Informations de copyright

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict-of-interest statement: The authors declare that they have no competing interests to report related to the work submitted for consideration of publication.

Références

Gastroenterology. 2021 Jan;160(1):145-157.e8
pubmed: 32681922
Gastroenterology. 2011 Jul;141(1):217-26, 226.e1-2
pubmed: 21600899
Am J Gastroenterol. 2015 Jun;110(6):802-19; quiz 820
pubmed: 25964225
Mediators Inflamm. 2015;2015:843089
pubmed: 26106258
Gut Microbes. 2015;6(6):364-9
pubmed: 26512631
Inflamm Bowel Dis. 2017 Sep;23(9):1600-1604
pubmed: 28590341
Inflamm Bowel Dis. 2008 Dec;14(12):1660-6
pubmed: 18623174
J Crohns Colitis. 2018 Nov 9;12(10):1180-1190
pubmed: 29985999
Nature. 2017 Jul 13;547(7662):173-178
pubmed: 28658209
Gut. 2006 Jun;55(6):749-53
pubmed: 16698746
Gastroenterology. 2006 Aug;131(2):366-78
pubmed: 16890590
Gut. 2017 Jun;66(6):1039-1048
pubmed: 26843508
Gastroenterology. 2004 Feb;126(2):414-24
pubmed: 14762777
Curr Treat Options Gastroenterol. 2015 Mar;13(1):105-20
pubmed: 25595930
Clin Gastroenterol Hepatol. 2011 May;9(5):421-7.e1
pubmed: 21334460
Clin Gastroenterol Hepatol. 2020 Oct;18(11):2518-2525.e1
pubmed: 31812654
J Immunol. 2010 Jun 1;184(11):6335-42
pubmed: 20421639
Gastroenterology. 2007 Jul;133(1):24-33
pubmed: 17631127
Gut. 2000 Oct;47(4):506-13
pubmed: 10986210
Gastrointest Endosc Clin N Am. 2019 Jul;29(3):421-436
pubmed: 31078245
Gastroenterology. 2011 May;140(6):1817-1826.e2
pubmed: 21530748
Front Biosci (Schol Ed). 2013 Jan 01;5:754-65
pubmed: 23277084
Gastrointest Endosc. 2004 Oct;60(4):505-12
pubmed: 15472670
Am J Gastroenterol. 2015 Sep;110(9):1324-38
pubmed: 26303131
PLoS One. 2013 Apr 24;8(4):e62016
pubmed: 23637950
Clin Gastroenterol Hepatol. 2020 Jul;18(8):1704-1718
pubmed: 31881273
Lancet. 1980 Mar 8;1(8167):514
pubmed: 6102236
J Biol Chem. 2006 Mar 3;281(9):5506-14
pubmed: 16407295
Lancet Gastroenterol Hepatol. 2018 Jan;3(1):17-24
pubmed: 29100842
Nature. 2019 May;569(7758):655-662
pubmed: 31142855
Scand J Gastroenterol. 2001 Apr;36(4):447-8
pubmed: 11336174
Gut. 2009 Apr;58(4):492-500
pubmed: 18832518
Intest Res. 2014 Apr;12(2):90-5
pubmed: 25349574
Clin Gastroenterol Hepatol. 2007 Dec;5(12):1430-8
pubmed: 18054751
Eur J Clin Invest. 1982 Aug;12(4):351-9
pubmed: 6814926
Clin J Gastroenterol. 2018 Feb;11(1):1-10
pubmed: 29285689
Inflamm Bowel Dis. 2012 Dec;18(12):2218-24
pubmed: 22344983
Intest Res. 2018 Jul;16(3):384-392
pubmed: 30090037
J Endocr Soc. 2020 Feb 20;4(2):bvz039
pubmed: 32099951
Inflamm Bowel Dis. 2005 Aug;11(8):707-12
pubmed: 16043984
Inflamm Bowel Dis. 2002 Jul;8(4):244-50
pubmed: 12131607
Inflamm Bowel Dis. 2008 Oct;14(10):1392-8
pubmed: 18484671
J Crohns Colitis. 2013 Oct;7(9):730-5
pubmed: 23182163
Gastroenterology. 2011 Oct;141(4):1194-201
pubmed: 21723220
Inflamm Bowel Dis. 2010 May;16(5):856-69
pubmed: 19924809
Gut. 2003 Jan;52(1):65-70
pubmed: 12477762
J Crohns Colitis. 2015 Jan;9(1):26-32
pubmed: 25008478
J Clin Invest. 2004 May;113(9):1296-306
pubmed: 15124021
Clin Gastroenterol Hepatol. 2014 Mar;12(3):414-22.e5
pubmed: 23856361
Immunology. 2013 Sep;140(1):87-97
pubmed: 23600521
J Crohns Colitis. 2014 Dec;8(12):1582-97
pubmed: 25267173
Gastroenterology. 1999 May;116(5):1029-34
pubmed: 10220494
Dig Liver Dis. 2017 May;49(5):457-458
pubmed: 28449813
Front Med (Lausanne). 2020 Apr 22;7:123
pubmed: 32391365
Dig Dis Sci. 2015 Oct;60(10):2953-62
pubmed: 25784074
Gut. 2016 Mar;65(3):408-14
pubmed: 25986946
Gastroenterol Res Pract. 2019 Dec 17;2019:3467316
pubmed: 31933630
Nat Immunol. 2007 Jun;8(6):630-8
pubmed: 17450144
J Biol Chem. 2010 Oct 1;285(40):30676-85
pubmed: 20643646
Gut. 1998 Jun;42(6):788-91
pubmed: 9691915
Nat Rev Gastroenterol Hepatol. 2017 Oct;14(10):573-584
pubmed: 28743984
J Crohns Colitis. 2017 Mar 1;11(suppl_2):S586-S592
pubmed: 27651219
J Gastroenterol Hepatol. 2003 Jul;18(7):756-62
pubmed: 12795745
Gut. 2012 Nov;61(11):1619-35
pubmed: 22842618
Arch Dis Child. 2020 Oct;105(10):996-998
pubmed: 30655264
Gut. 2000 Sep;47(3):404-9
pubmed: 10940279
Gastroenterology. 2019 Oct;157(4):1007-1018.e7
pubmed: 31279871
Eur J Gastroenterol Hepatol. 2018 Oct;30(10):1125-1129
pubmed: 30004906
N Engl J Med. 2011 Jan 6;364(1):22-32
pubmed: 21208106
Curr Treat Options Gastroenterol. 2017 Mar;15(1):116-125
pubmed: 28161818
J Leukoc Biol. 2011 Aug;90(2):357-66
pubmed: 21531876
Gut. 2009 Aug;58(8):1113-20
pubmed: 19136510
J Crohns Colitis. 2015 Jan;9(1):50-5
pubmed: 25518048
Inflamm Bowel Dis. 2011 Mar;17(3):767-77
pubmed: 20865702
J Crohns Colitis. 2020 Feb 10;14(2):254-266
pubmed: 31403666
United European Gastroenterol J. 2017 Aug;5(5):702-707
pubmed: 28815034
Immunobiology. 2013 Nov;218(11):1428-37
pubmed: 23932568
Inflamm Bowel Dis. 2016 Mar;22(3):623-30
pubmed: 26829408
Gastroenterology. 2014 Feb;146(2):374-82.e1
pubmed: 24177375
N Engl J Med. 1987 Dec 24;317(26):1625-9
pubmed: 3317057
Gastroenterology. 1990 Oct;99(4):956-63
pubmed: 2394349
Inflamm Bowel Dis. 2007 Mar;13(3):269-77
pubmed: 17206721

Auteurs

Katia Farias E Silva (K)

Department of Clinical Medicine, School of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro 21941-913, Brazil.

Hayandra F Nanini (HF)

Department of Clinical Medicine, School of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro 21941-913, Brazil.

Cynthia Machado Cascabulho (CM)

Laboratory of Innovations in Therapies, Education and Bioproducts, Instituto Oswaldo Cruz, Rio de Janeiro 21040-360, Brazil.

Siane L B Rosas (SLB)

Department of Clinical Medicine, School of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro 21941-913, Brazil.

Patricia T Santana (PT)

Department of Clinical Medicine, School of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro 21941-913, Brazil.

Antonio José de V Carneiro (AJV)

Department of Clinical Medicine, School of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro 21941-913, Brazil.

Elias Anaissie (E)

Clinical Trial and Consulting Services, Cincinnati, OH 45267, United States.

Marcio Nucci (M)

Department of Clinical Medicine, School of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro 21941-913, Brazil.

Heitor Siffert Pereira de Souza (HSP)

Department of Clinical Medicine, School of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro 21941-913, Brazil. hsouza@hucff.ufrj.br.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH